Tanikaze Saburo, Osa Yuichi, Tada Minoru, Goya Nobuyuki, Asanuma Hiroshi, Yamazaki Yuichiro, Shimada Kenji, Sugita Yoshifumi, Goto Takafumi, Yamaguchi Takanori
Department of Urology, Aichi Children's Health and Medical Center.
Nihon Hinyokika Gakkai Zasshi. 2010 Jul;101(5):676-82. doi: 10.5980/jpnjurol.101.676.
To investigate the efficacy and safety of endoscopic treatment with the injectable gel of dextranomer beads in stabilized non-animal sodium hyaluronate (NASHA/Dx gel) administered submucosally close to the proximity of ureteral orifice, we performed the multi-center open study of Japanese patients with vesicoureteral reflux (VUR). We herein report the results of the study.
Patients aged > or = 1 year with grade II-IV VUR underwent endoscopic injection with NASHA/Dx gel. Post-treatment assessment was done by voiding cystourethrography (VCUG) at 3 and 12 months. Patients with VUR grade II-IV at 3 months underwent re-treatment, with VCUG assessment 3 and 12 months after retreatment. Positive response to treatment was defined as reflux grade 0 or 1.
The initial treatment was conducted to 116 ureters in 73 patients. The per-protocol efficacy population included 97 ureters in 71 patients. On a per-ureter basis, the positive response rate at 12 months after the last endoscopic treatment was 69.1%, compared with 62.0% on a per-patient basis. Improvement in reflux grade was shown to be statistically significant at both 3 months post initial treatment and 12 months post last treatment. Positive response rate decreased with increasing baseline reflux grade. There were only two mild adverse events (AEs) and one moderate laboratory fluctuation which were potentially relating to NASHA/Dx gel.
This study has shown that endoscopic injection of NASHA/Dx gel is effective and well tolerated in Japanese patients with VUR. First-line use of this treatment for VUR could potentially be considered for Japan also.
为了研究在输尿管口附近黏膜下注射稳定的非动物透明质酸钠(NASHA/Dx凝胶)进行内镜治疗的疗效和安全性,我们对日本膀胱输尿管反流(VUR)患者进行了多中心开放研究。我们在此报告该研究结果。
年龄≥1岁的II-IV级VUR患者接受NASHA/Dx凝胶内镜注射治疗。在治疗后3个月和12个月通过排尿性膀胱尿道造影(VCUG)进行评估。3个月时仍为II-IV级VUR的患者接受再次治疗,并在再次治疗后3个月和12个月进行VCUG评估。治疗阳性反应定义为反流分级为0或1级。
对73例患者的116条输尿管进行了初始治疗。符合方案的疗效人群包括71例患者的97条输尿管。以每条输尿管为基础,最后一次内镜治疗后12个月的阳性反应率为69.1%,以每位患者为基础则为62.0%。在初始治疗后3个月和最后一次治疗后12个月,反流分级的改善均具有统计学意义。阳性反应率随基线反流分级的增加而降低。仅出现2例轻度不良事件(AE)和1例中度实验室波动,可能与NASHA/Dx凝胶有关。
本研究表明,内镜注射NASHA/Dx凝胶对日本VUR患者有效且耐受性良好。在日本也可考虑将这种治疗作为VUR的一线治疗方法。